Addiction to Cannabis Clinical Trial
— TCCOfficial title:
Evaluation of the Effect of tDCS on Cannabis Craving: Multicentre Randomized, Double-blind Study Versus Placebo
Cannabis is the most frequently consumed drug in France and its use continues to increase.
Over the 18-64 age group as a whole, experimentation with cannabis at least once in a
lifetime increased from 33% in 2010 to 42% in 2014, confirming the upward trend observed
since the 1990.
Cannabis, like all drugs, disrupts the reward circuit whose neurons originate in the ventral
tegmental area and project into the mesolimbic and cortical structures.
Acute cannabis use is thought to increase mesolimbic dopamine by affecting the Gabaergic or
Glutamatergic system.
Chronic cannabis use usurps the reward system and leads to changes in the mesolimbic circuit
(nucleus accumbens, ventral tegmental area, amygdala, and prefrontal cortex), inducing
increased craving, with persistent craving for the substance and vulnerability to relapse.
Cognitively, addiction is associated with increased impulsivity, with a propensity to take
risks leading to impaired decision-making.
There is currently no validated drug treatment for cannabis addiction. Non-invasive brain
stimulation could be an interesting therapeutic alternative.
| Status | Recruiting |
| Enrollment | 78 |
| Est. completion date | December 17, 2021 |
| Est. primary completion date | July 17, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 63 Years |
| Eligibility |
Inclusion Criteria: 1. Men or women between 18 and 65 years of age 2. Right-Handers 3. Diagnosis: Cannabis Use Disorder (according to DSM 5 criteria) 4. Patient with no other drug or psychotherapeutic treatment for cannabis addiction ("naive" patients) 5. Reported use of cannabis more than three times a week in the past three years 6. Signing consent to participate in research Exclusion Criteria: 1. Pregnancy or lack of effective contraception 2. Patients with severe somatic disease 3. Other addictions of "moderate" to "severe" intensity according to DSM 5 criteria (excluding tobacco and coffee) 4. Patients undergoing antidepressant or neuroleptic or thyroid-regulating therapy. 5. Contraindications to tDCS (presence of an intracranial metal body, intracranial hypertension) 6. Topic that has already been stimulated by tDCS 7. Patients under reinforced guardianship or curatorship |
| Country | Name | City | State |
|---|---|---|---|
| France | Youcef BENCHERIF | Maisons Alfort | Île De France |
| Lead Sponsor | Collaborator |
|---|---|
| Januel |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Evaluating the change from craving to cannabis. by an analog visual scale .Scores (0 to 10) | 3 months | ||
| Secondary | The change to cannabis craving assessed by the Baseline Marijuana Craving Test at the end of treatment | 3 month | ||
| Secondary | The change in cannabis craving during an incentive to use task evaluated by analog visual scale scores (0 to 10) | 3 months | ||
| Secondary | Montgomery-Åsberg depression rating scale) Scores (0 to 60) | 3 months | ||
| Secondary | evaluation of the change in the number of joints consumed per day | 3 months | ||
| Secondary | evaluation of the change in the number of cigarettes consumed per day | 3 months | ||
| Secondary | assessment of the change in attention and inhibition skills as assessed by the Stroop test before and after a neurofeedback test | 3 months | ||
| Secondary | the Gambling Task's assessment of decreased risk-taking | 3 months | ||
| Secondary | Young Mania Rating Scale Scores (0 to 60) | 3 months | ||
| Secondary | Beck Depression Inventory Scores (0 to 39) | 3 months | ||
| Secondary | Clinical Global Impression Severity of disease (0 to 7) | 3 months |